# National Center for Health Statistics (NCHS), ICD-10 Coordination and Maintenance (C&M) Committee Meeting
**AGENCY:**
Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).
**ACTION:**
Notice of meeting.
**SUMMARY:**
The CDC, National Center for Health Statistics (NCHS), Classifications and Public Health Data Standards Staff, announces the following meeting of the ICD-10 Coordination and Maintenance (C&M) Committee meeting. This meeting is open to the public, limited only by audio and web conferences lines available. Online Registration is not required.
**DATES:**
The meeting will be held on September 8, 2020, from 9:00 a.m. to 5:00 p.m., EDT, and September 9, 2020, from 9:00 a.m. to 5:00 p.m., EDT.
**ADDRESSES:**
This is a virtual meeting. Information will be provided on each of our respective web pages when it becomes available. For CDC/NCHS *https://www.cdc.gov/nchs/icd/icd10cm_maintenance.htm.*
For CMS *https://www.cms.gov/Medicare/Coding/ICD9ProviderDiagnosticCodes/meetings.*
**FOR FURTHER INFORMATION CONTACT:**
Traci Ramirez, Program Specialist, CDC, 3311 Toledo Road, Hyattsville, Maryland 20782, Telephone (301) 458-4454; *[email protected].*
**SUPPLEMENTARY INFORMATION:**
*Purpose:* The ICD-10 Coordination and Maintenance (C&M) Committee is a public forum for the presentation of proposed modifications to the International Classification of Diseases, Tenth Revision, Clinical Modification and ICD-10 Procedure Coding System.
*Matters To Be Considered:* The tentative agenda will include discussions on ICD-10-CM and ICD-10-PCS topics listed below. Agenda items are subject to change as priorities dictate.
Please refer to the posted agenda for updates one month prior to the meeting.
**ICD-10-PCS Topics**
Vertebral Body Tethering
Removal of a Transplanted/Rejected Kidney
Isotope Administration
Administration of Lifileucel
Administration of Narsoplimab
Insertion of Implantable Bone Void Filler
Single-Use Duodenoscope
Administration of Immune Effector Cell Therapy
Spinal Stabilization
Administration of Idecabtagene Vicleucel (ide-cel)
Restriction of Coronary Sinus
Embolic Protection
**ICD-10-CM Topics:**
Complications of immune effector cellular (IEC) therapy
Endometriosis
Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) Addenda
The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign *Federal Register* notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.
Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.